Thymalfasin: Molecular Characterization, Immunomodulatory Mechanisms, and Multisystem Preclinical and Clinical Research

by | Nov 11, 2026 | Research

Thymalfasin, the international non-proprietary name for Thymosin Alpha-1 (Tα1), is a naturally occurring, N-terminally acetylated 28-amino acid peptide originally isolated from bovine thymic tissue.[1][2] Its primary amino acid sequence is Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH.2 Thymalfasin is highly acidic in character, with a net negative charge under physiological conditions arising from multiple aspartate and glutamate residues distributed throughout its sequence.[2][3]
 

Thymalfasin Overview

Thymalfasin is biosynthetically derived from a larger 109-amino acid precursor protein, prothymosin alpha, through post-translational proteolytic processing that releases the 28-residue active peptide.[1][2] This precursor-product relationship was characterized by Haritos and colleagues, who identified prothymosin alpha as the dominant immunoreactive form in rat thymus and blood. Endogenous thymalfasin-like immunoreactivity has been demonstrated in the thymus, spleen, peripheral blood mononuclear cells, and several extralymphoid tissues, consistent with a broad immunoregulatory role beyond primary lymphoid organs.[5]

Thymalfasin is a linear peptide with no disulfide bonds or glycosylation sites. Its highly acidic pI, estimated at approximately 4.2, arises from nine anionic residues (Asp and Glu) against three cationic residues (Lys) within the 28-amino acid chain.[2][3] Studies examining the peptide’s membrane insertion behavior suggest that the amphiphilic character conferred by its hydrophobic N-terminal acetyl group and polar central and C-terminal domains may contribute to interactions with lipid bilayers relevant to cell signaling initiation.[5]

Research suggests thymalfasin exerts its immunomodulatory effects through interaction with multiple Toll-like receptors (TLRs), specifically TLR2, TLR3, TLR4, TLR7, and TLR9.[5] These interactions are proposed to activate downstream signaling pathways including NF-κB, interferon regulatory factors IRF3 and IRF7, MyD88-dependent cascades, and mitogen-activated protein kinase (MAPK) pathways, collectively driving cytokine secretion and innate immune activation. Additionally, research indicates that thymalfasin may upregulate major histocompatibility complex (MHC) antigen expression on antigen-presenting cell surfaces, potentially augmenting antigen display and T lymphocyte priming.[5]

 

Thymalfasin Scientific and Research Studies

 

T-Lymphocyte Differentiation and Th1 Immunopolarization

A central focus of thymalfasin research concerns its capacity to modulate T-lymphocyte maturation, differentiation, and functional polarization.⁵ Research suggests thymalfasin may promote differentiation of CD8+ cytotoxic T lymphocytes and drive CD4+ helper T cell responses toward the Th1 immunophenotype, characterized by enhanced secretion of interferon-gamma (IFN-γ) and interleukin-2 (IL-2).[5] These observations are speculated to be consistent with a broad immunorestorative profile relevant to states of immune deficiency or dysfunction.

In preclinical models, thymalfasin is said to enhance natural killer (NK) cell cytotoxic activity and augment dendritic cell phagocytic function alongside IL-12 secretion.[5] Activation of bone marrow-derived macrophages by thymalfasin results in reported increased production of IL-6, IL-10, and IL-12, suggesting activity across multiple innate immune cell lineages. Research suggests these findings might indicate a hierarchically organized immunomodulatory program in which thymalfasin engages both innate sentinel cells and the adaptive lymphocyte compartment. The magnitude of thymalfasin’s immunostimulatory effect may be context-dependent, with reported bidirectional immunoregulatory activity under conditions of excessive immune activation.[5]

 

Chronic Hepatitis B: Phase III Randomized Trial

A Phase III multicentre, randomized, double-blind, placebo-controlled study[6] investigated thymalfasin in adult mammalian models with chronic hepatitis B virus (HBV) infection. Mammalian models were randomized to receive subcutaneous thymalfasin or placebo twice weekly for 12 months, with follow-up extended to assess sustained virological responses.

Findings suggested that thymalfasin-exposed mammalian models demonstrated significantly higher rates of hepatitis Be antigen (HBeAg) seroconversion and normalization of serum alanine aminotransferase (ALT) levels compared with placebo recipients at the end of study and follow-up.[6] The response profile was characterized by gradual improvement over the study course, consistent with a mechanism relying on progressive immunological restoration rather than direct antiviral activity. Tolerability was reported as generally favorable, with injection-site reactions as the predominant adverse event. Research suggests these results might indicate a role for host immune reconstitution in the resolution of chronic HBV infection, mediated at least in part through thymalfasin’s support of HBV-specific T lymphocyte responses.

 

Chronic Hepatitis C: Double-Blind Pilot Trial

Andreone et al. (1996)[7] conducted a randomized, double-blind, placebo-controlled pilot investigation of thymalfasin in certain mammalian models with biopsy-confirmed chronic hepatitis C virus (HCV) infection. Participants received thymalfasin (900 µg/m² twice weekly) or placebo for six months, followed by a six-month observation period. All mammalian models completed the full study duration.

Findings suggested that one thymalfasin-exposed subject achieved ALT normalization, though this response was not sustained at the six-month follow-up evaluation. No placebo recipient normalized ALT. The investigators suggested that this particular thymalfasin regimen was not sufficient as monotherapy for chronic HCV infection, though the limited sample size and fixed-dose design constrain the interpretive scope of these findings. Subsequent research has examined thymalfasin in combination with PEGylated interferon, with one reported cohort reportedly demonstrating a sustained viral response rate of 41.0% versus 26.3% in controls, suggesting that combination approaches may produce more pronounced effects than monotherapy.

 

Sepsis: Toll-Like Receptor Signaling Modulation

A prospective randomized investigation by Tang et al. (2014)[8] enrolled mammalian models with severe sepsis to evaluate whether thymalfasin modulates Toll-like receptor-mediated innate immune signaling in the clinical setting. 26 mammalian models received thymalfasin alongside standard care, and 28 received standard care alone. Peripheral blood mononuclear cell (PBMC) mRNA expression levels of TLR2, TLR4, and MyD88 were quantified by RT-PCR at baseline, day 3, and day 7.

Findings suggested that TLR2 and TLR4 mRNA expression were significantly elevated in the thymalfasin-exposed group compared with controls at day 3, with the differential persisting through day 7 alongside a significant increase in MyD88 expression.[8] The 28-day mortality was 23.1% in the thymalfasin group versus 35.7% in controls, though this difference did not reach statistical significance (P=0.310). Research suggests these findings might indicate that thymalfasin enhances innate pattern recognition receptor signaling in sepsis, a clinically relevant observation given that immunosuppression and blunted TLR responsiveness are recognized features of sepsis-associated immune dysregulation.

 

Sepsis: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Gu et al. (2025)[9] conducted a systematic review and meta-analysis pooling 11 randomized controlled trials encompassing 967 mammalian models receiving thymalfasin and 960 control mammalian models to evaluate its effect on 28-day mortality in sepsis. Trial sequential analysis and a heterogeneity of study effects subgroup analysis using individual subject data from two large trials were incorporated to refine inference.

Overall findings suggested that thymalfasin was associated with reduced 28-day mortality across the pooled mammalian model population.[9] However, the mortality benefit was not statistically significant when analyses were restricted to higher-quality trials or to multicenter studies. Subject-level subgroup analyses identified possible benefit signals in participants with concurrent cancer, diabetes, and coronary heart disease, though the credibility of these subgroup findings was rated as moderate to low. Trial sequential analysis indicated that the current aggregate sample size remained insufficient for definitive conclusions. The authors noted that all included trials were conducted in China and that funnel plot asymmetry suggested possible publication bias. Research suggests these findings might indicate a meaningful but not yet conclusively established mortality benefit for thymalfasin in sepsis, with personalized immunotherapy strategies and larger multinational trials warranted.

 

Mammalian dImmuno-Oncology: Combination with Immune Checkpoint Inhibitors

Guo and Li (2026)[10] published a comprehensive review examining the scientific rationale and emerging clinical evidenata ce for combining thymalfasin with immune checkpoint mitigators. The review addressed the immunosuppressive tumor microenvironment as a recognized barrier to ICI efficacy, particularly the accumulation of myeloid-derived suppressor cells (MDSCs) and M2-polarized tumor-associated macrophages that attenuate antitumor immunity.

Preclinical findings cited in the review suggested that thymalfasin may reduce MDSC infiltration and M2 macrophage populations within the tumor microenvironment, potentially shifting tumors from an immune-excluded toward a more immunologically active state.[10] In animal models, peritumoral IDO1 expression and regulatory T cell numbers were reported to be elevated alongside increased intratumoral CD4+ and CD8+ T cell infiltration following thymalfasin exposure.

Regarding ICI-associated toxicity, preclinical data suggested that thymalfasin may reduce intestinal immunopathology associated with CTLA-4 mitigation without diminishing antitumor activity. Early-phase clinical observations described a notable objective response rate in locally advanced colorectal cancer, a major pathological response rate in stage III gastric cancer, and a significant disease control rate in elderly mammals with stage IV melanoma in ICI combination. A retrospective analysis in unresectable non-small cell lung cancer reported longer progression-free and overall survival alongside fewer cases of grade ≥2 pneumonitis in the thymalfasin-containing arm. Research suggests these early clinical observations might indicate a synergistic immunomodulatory relationship between thymalfasin and checkpoint inhibition, though the authors emphasize that larger, randomized, multicenter trials are required to characterize this relationship definitively.

 

Respiratory Illness in Mammalian Models: Systematic Review and Meta-Analysis

Wang, Wang, and Chen (2023)[11] conducted a systematic review and meta-analysis of nine studies encompassing over 5000 participants to evaluate thymalfasin’s clinical efficacy in ill mammalian models, drawing on data through July 2023. Risk of bias was assessed using the Newcastle-Ottawa Scale and Cochrane methodology. Overall, thymalfasin was not associated with a statistically significant reduction in mortality across the pooled population, and no significant reduction in overall hospitalization duration was identified. However, subgroup analyses suggested differential interactions by disease severity: in mammalin models with severe or critical illness, thymalfasin was associated with reduced mortality, while in mild-to-moderate disease, it was associated with shorter hospitalization duration without a significant mortality difference.

This analysis was constrained by high overall heterogeneity, inclusion of only two randomized controlled trials, and a predominance of studies from China, which the authors acknowledged limited generalizability. Research suggests these findings might indicate that thymalfasin’s immunostimulatory properties confer more pronounced benefit in severe immunologically dysregulated viral disease states than in milder presentations, consistent with its proposed mechanism of restoring deficient adaptive immune function.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

  1. Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA. 1966;56(3):1010-7. doi:10.1073/pnas.56.3.1010. PMID: 5230175. Available from: https://pubmed.ncbi.nlm.nih.gov/5230175/
  2. Goldstein AL, Low TLK, McAdoo M, McClure J, Thurman GB, Rossio J, et al. Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725-9. doi:10.1073/pnas.74.2.725. PMID: 265536. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC392366/
  3. National Center for Biotechnology Information. PubChem Compound Summary for CID 16130571, Thymalfasin (Thymosin Alpha-1). CAS 62304-98-7. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/16130571
  4. Low TLK, Hu S-K, Goldstein AL. Complete amino acid sequence of bovine thymosin β4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. J Biol Chem. 1979;254(3):987-95. PMID: 216684. Available from: https://pubmed.ncbi.nlm.nih.gov/216684/
  5. Tao N, Xu X, Ying Y, Hu S, Sun Q, Lv G, Gao J. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules. 2023;28(8):3539. doi:10.3390/molecules28083539. Available from: https://www.mdpi.com/1420-3049/28/8/3539
  6. Peng L, Zhu Y, Jiang N, Chen W, Wu M, Zheng S, et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. Aliment Pharmacol Ther. 2000;14(2):199-203. doi:10.1046/j.1365-2036.2000.00700.x. PMID: 10607256. Available from: https://pubmed.ncbi.nlm.nih.gov/10607256/
  7. Andreone P, Cursaro C, Gramenzi A, Zavaglia C, Rezakovic I, Altomare E, et al. A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver. 1996;16(3):207-10. doi:10.1111/j.1600-0676.1996.tb00727.x. PMID: 8873009. Available from: https://pubmed.ncbi.nlm.nih.gov/8873009
  8. Tang Z, Wu J, Chen J, Ouyang B, Chen M, Guan X. Changes of TLR2, TLR4, MYD88 mRNA expressions on peripheral blood mononuclear cell in severe sepsis subjects during treatment with thymosin α1. Intensive Care Med Exp. 2014;2(Suppl 1):O7. doi:10.1186/2197-425X-2-S1-O7. PMCID: PMC4796653. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4796653/
  9. Gu B, Zhou Y, Nie Y, Wang L, Liang L, Liao Z, Wen J, Guan X, Chen M, Wu J, Pei F. Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2025;15:1673959. doi:10.3389/fcimb.2025.1673959. Available from: https://pdfs.semanticscholar.org/1c07/ffc733ad84366ed59edd6b017875de397645.pdf
  10. Guo H, Li R. Thymosin α1 combined with immune checkpoint inhibitors: synergistic remodeling of the tumor immune microenvironment to enhance clinical efficacy and safety. Front Immunol. 2026;17:1762151. doi:10.3389/fimmu.2026.1762151. PMID: 42292432. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC13260598/
  11. Wang P, Wang C, Chen D. Efficacy of thymosin-α-1 in subjects with COVID-19: A systematic review and meta-analysis. Eur J Inflamm. 2023;21. doi:10.1177/1721727X231197922. Available from: https://journals.sagepub.com/doi/full/10.1177/1721727X231197922
  12. Haritos AA, Goodall GJ, Horecker BL. Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus and blood. Proc Natl Acad Sci USA. 1984;81(4):1008-11. doi:10.1073/pnas.81.4.1008. PMID: 6583664. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC344752/

Dr. Usman

Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.